RAPT Therapeutics (RAPT) Research & Development (2020 - 2023)
Historic Research & Development for Therapeutics (RAPT) over the last 4 years, with Q4 2023 value amounting to $26.8 million.
- Therapeutics' Research & Development rose 3757.58% to $26.8 million in Q4 2023 from the same period last year, while for Dec 2023 it was $101.0 million, marking a year-over-year increase of 5056.5%. This contributed to the annual value of $101.0 million for FY2023, which is 5056.5% up from last year.
- Per Therapeutics' latest filing, its Research & Development stood at $26.8 million for Q4 2023, which was up 3757.58% from $27.0 million recorded in Q3 2023.
- Therapeutics' Research & Development's 5-year high stood at $27.0 million during Q3 2023, with a 5-year trough of $10.7 million in Q1 2020.
- Over the past 4 years, Therapeutics' median Research & Development value was $15.0 million (recorded in 2021), while the average stood at $16.9 million.
- In the last 5 years, Therapeutics' Research & Development surged by 555.8% in 2022 and then surged by 6279.29% in 2023.
- Quarter analysis of 4 years shows Therapeutics' Research & Development stood at $10.9 million in 2020, then soared by 31.14% to $14.3 million in 2021, then surged by 36.05% to $19.5 million in 2022, then surged by 37.58% to $26.8 million in 2023.
- Its Research & Development was $26.8 million in Q4 2023, compared to $27.0 million in Q3 2023 and $21.6 million in Q2 2023.